BioNexus Gene Lab Corp. Write off of Deferred Debt Issuance Cost
BioNexus Gene Lab Corp. (BGLC) reported Write off of Deferred Debt Issuance Cost of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2026-04-14
- BioNexus Gene Lab Corp. write off of deferred debt issuance cost for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BioNexus Gene Lab Corp. write off of deferred debt issuance cost for fiscal 2024 was $6.34K.
| Period end | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-14 |
| 2024-12-31 | $6.34K 10-K · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |